Pharma Mar stock
PHM.MCBMEPharma Mar, S.A., HealthcareISIN ES0169501022
59Score 59 out of 100, Neutral
Price and trend
43 / 100
Price history
−8.6% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 16% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 34% below its 52-week high. Largest decline in 20 years: 90% (July 2007 to October 2018).
Chart figures for advanced users
- SMA 50$79.01
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$90.18
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$71.20
- The lowest closing price of the last twelve months.
- Resistance$114.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pharma Mar, S.A. belongs to the Biotechnology industry (Spain) and, with a market value of $1.31B, is number 165 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $245.32M (up 26.6% year on year) and earnings of $83.09M (up 187%).
- For fiscal 2026, analysts expect on average revenue of $236.03M (down 3.8%) and adjusted earnings per share of $1.92 (down 60.9%).
Show more
- MEQIRI Score 59 out of 100 (Neutral): rank 283 of 702 in Healthcare, median 53.
- The P/E is 17.3 (Biotechnology median 21.7, own median of recent years 17.4).
- Our model puts fair value at $211.23, with the price 64% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 66.8% a year through 2028 (estimates from 6 analysts).
- High return on capitalReturn on invested capital 33.7% in fiscal 2025, Biotechnology median −24.3%.Profitability 92
- High marginNet margin 28.8% over the last 12 months, Biotechnology median −103.7%.Profitability 92
Weaknesses
- Revenue shrinkingRevenue down 3.9% a year since 2020.Growth 10
- Earnings per share fallingDown 10.5% a year since 2020.Growth 10
Its standout strengths are profitability and capital allocation, while momentum and growth hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
What lowers it
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $150.88 and expensive above $352.04 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $327.54 (cash-flow model) and $94.92 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 10.3%. At 11.3% the fair value would be $186.17, at 9.3% it would be $244.65.
Possible value trap: looks cheap, but weak growth.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 32.4% on the twelve months before. Revenue has grown solidly since 2006, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 94%, operating 18%, net 34%. Last 12 months: net 29%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 1 Mar 2027in 108 days
- Last reported
- 29 Oct 2026EPS reported $0.53 (expected $0.14)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 41.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $1.92−4.1%
- Revenue
- $236.03M+0.3%
- Earnings per share
- $3.99−41.8%
- Revenue
- $316.29M−6.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Pharma Mar
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Tyra BiosciencesTYRA $1.36B36
- Avalyn PharmaAVLN $1.36B41
- InnovivaINVA $1.35B67
- MannKindMNKD $1.34B39
- OmerosOMER $1.3B52
- UroGen PharmaURGN $1.29B36
- Inhibrx BiosciencesINBX $1.29B33
- COMPASS PathwaysCMPS $1.28B35
ETFs that hold Pharma Mar
Held by 20 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 1.92% | 0.49% | €26.29M |
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.17% | 0.28% | €630.46M |
| WisdomTree Eurozone Quality Dividend Growth UCITS ETF EUR AccWTIM | 0.14% | 0.29% | €49.19M |
Show 5 more
| WisdomTree Europe SmallCap Dividend UCITS ETF AccWTD7 | 0.11% | 0.38% | €86.74M |
| Xtrackers Spain UCITS ETF 1DXESD | 0.11% | 0.30% | €511.41M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.10% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.08% | 0.40% | €813.42M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.08% | 0.40% | €580.62M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.